Osteoporos Sarcopenia.  2021 Sep;7(3):89-91. 10.1016/j.afos.2021.09.002.

Romosozumab and cardiovascular safety in Japan

• Takeuchi Y

• KMID: 2520667
• DOI: http://doi.org/10.1016/j.afos.2021.09.002

Abstract

Romosozumab is a potent pharmacological tool to prevent fractures in osteoporosis patients, and its mechanism of action is distinct from any other drugs. The efficacy of romosozumab to prevent osteoporotic fractures is remarkable. However, there remains a concern of increased cardiovascular adverse events. Further relevant investigations are essential to understand whether romosozumab is actually involved in the development of cardiovascular events or not. We need more robust evidence to establish an appropriate and reasonable guide to prescribe romosozumab in our clinical practice.

Keyword

Romosozumab; Sclerostin; Cardiovascular event; Cerebrovascular event; Pharmacovigilance study